TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Polyrizon Ltd. ( (PLRZ) ) has provided an update.
On December 2, 2025, Polyrizon Ltd. announced the successful completion of a significant manufacturing upscaling milestone for its nasal spray platform. This achievement transitions their PL-14 formulation from small-batch to large-scale production, ensuring high-quality standards are met. The milestone is crucial for supporting upcoming clinical trials expected in 2026 and aligns with regulatory standards in the USA and Europe, marking a step towards potential commercial readiness and addressing unmet needs in the nasal spray market.
More about Polyrizon Ltd.
Polyrizon Ltd. is a biotechnology company specializing in the development of innovative medical device hydrogels delivered as nasal sprays. These products form a hydrogel-based barrier in the nasal cavity to protect against viruses and allergens. The company’s proprietary Capture and Contain (C&C) hydrogel technology is designed to function as a ‘biological mask,’ and they are also exploring intranasal delivery of drugs through their Trap and Target (T&T) technology.
Average Trading Volume: 181,326
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.15M
For detailed information about PLRZ stock, go to TipRanks’ Stock Analysis page.